Form 4: Adverum Biotechnologies Director Granted Stock Options

Adverum Biotechnologies, Inc. director Dawn Svoronos was granted 10,450 stock options with an exercise price of $2.32, vesting by June 2026.

Summary

• Dawn Svoronos, a Director of Adverum Biotechnologies, Inc. (ADVM), was granted 10,450 stock options.
• The stock options have an exercise price of $2.32 per share.
• The options are set to vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is contingent upon Ms. Svoronos's continued service with the Issuer on the vesting date.
• Accelerated vesting will occur upon a change of control.
• The expiration date for these stock options is June 16, 2035.

Sentiment

Score: 6

Explanation: The filing reports a standard grant of stock options to a director, which is a routine compensation event and generally viewed as a positive alignment of interests, without indicating any significant negative or unexpected developments.

Positives

• The grant of stock options to Director Dawn Svoronos aligns her interests with those of shareholders, incentivizing long-term performance.
• The options have a long expiration date of June 16, 2035, providing a significant window for potential value realization.

Negatives

• No direct negative implications are apparent from this Form 4 filing, which reports a standard equity grant to a director.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The options are set to vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, subject to continued service and accelerated vesting upon a change of control.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This Form 4 filing details a specific insider equity grant and does not contain information suitable for comparison to industry-wide financial or operational benchmarks.

Related Party Transactions

• The grant of 10,450 stock options to Dawn Svoronos, a director of Adverum Biotechnologies, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align management incentives with shareholder value creation.

Next Steps

• Vesting of 10,450 stock options on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Potential exercise of vested stock options by Dawn Svoronos.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, stock option, insider transaction, Form 4, director compensation, equity grant